CD55 is over-expressed in the tumour environment by Li, L et al.
CD55 is expressed on cells to protect them from complement
attack. It is therefore present on all cells that are exposed to
complement including red blood cells, leukocytes, endothelial
cells and epithelial cells. CD55 binds C3 convertases from both
the classical and alternative complement pathways preventing C3b
deposition and inhibiting the downstream assembly of the
membrane attack complex. CD55 is a GPI-anchored protein
composed of 4 contiguous short consensus repeat (SCR) domains
and a Serine/Threonine (S/T) rich region proximal to the cell
surface (Nicholson-Weller and Wang, 1994). 
791Tgp72 is a tumour associated antigen which has been used
successfully as a target for tumour imaging with the mouse mono-
clonal antibody 791T/36. Osteosarcomas, ovarian, gastric and
colorectal tumours have been successfully imaged with lesions 
as small as 1 cm3 being detected (Farrands et al, 1982, 1983;
Armitage et al, 1985). A human monoclonal anti-idiotypic anti-
body 105AD7 was shown to mimic the 791Tgp72 antigen (Austin
et al, 1989) and stimulate anti-tumour T cell responses in cancer
patients without any associated toxicity. A phase I study in
advanced colorectal cancer patients demonstrated enhanced
plasma IL-2 production, conversion of both CD4 and CD8 cells
from CD45 RA (naïve) to CD45 RO (memory) cells (Durrant et al,
2000) and in vitro blastogenesis responses to tumour cells
expressing 791Tgp72 (Denton et al, 1994). In a neoadjuvant study
patients were immunized pre-operatively and boosted following
resection of their colorectal tumours. Tumours from the immunized
group showed enhanced infiltration of CD4 and CD56 cells com-
pared to unimmunized tumours. Infiltration of CD56 cells corre-
lated well with enhanced NK activity (Durrant et al, 1999). There
was also enhanced killing of autologous tumour cells which was
unrelated to NK killing (Durrant et al, 1994) and a three-fold
increase in tumour cell apoptosis. 
791Tgp72 has recently been characterized as CD55 (Spendlove
et al, 1999) and it was of interest to establish why CD55 was a
target for tumour immunotherapy, despite its apparent ubiquitous
expression. Expression of CD55 in the tumour environment was
therefore studied. 
MATERIALS AND METHODS 
Cells 
791T and MG63 are osteosarcoma cell lines. Colo205, C170,
SW480, PT01, HT29 are all colorectal cell lines whereas MKN45
and MKN45K are both gastric cell lines. All cell lines were grown
in RPMI (Gibco, BRL, Paisley, UK) supplemented with 10% heat
inactivated fetal calf serum. Red blood cells and lymphocytes were
isolated from the same peripheral blood sample by centrifugation
through Ficoll. Leukocytes were collected at the Ficoll/serum
interface and red blood cells were pelleted to the bottom of the
tube. Monocytes were obtained following overnight plastic adher-
ence of Ficoll-purified leukocytes. Human umbilical vein endothe-
lial cells (HUVEC) were isolated by the method of Jaffe (Jaffe 
et al, 1972). Endothelial cells were maintained in growth medium
consisting 1:1 of M199 and Ham F12 nutrient mixture (Sigma,
Dorset, UK) supplemented with 0.014 M N-(2-hydroxyethyl)
piperazine-N'-(2-hydroxy-propane) sulphonic acid (HEPES),
0.15% sodium bicarbonate, 2 mM L-glutamine, 10 U ml–1 peni-
cillin/10 U ml–1 streptomycin (Sigma), 30% (v/v) fetal calf serum
(Gibco-BRL), 15 U ml–1 heparin and 40 U ml–1 endothelial cell
growth supplement (Boehringer Mannheim, Lewes, UK) and
passed at a 1:3 split ratio onto 0.2% gelatine-coated flasks.
Upregulation of CD55 by either tumour-conditioned medium or
VEGF was demonstrated by splitting cells 1:3 in 1:1 mix of fresh
CD55 is over-expressed in the tumour environment 
L Li, I Spendlove, J Morgan and LG Durrant 
CRC Academic Unit of Clinical Oncology, University of Nottingham, City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK 
Summary CD55 is a protein that protects cells from complement-mediated attack. 791Tgp72 is an antigen which has been used succes-
fully as a target for both tumour imaging and cancer vaccines. 791Tgp72 has recently been identified as CD55. Quantitative expression of
CD55 in the tumour environment was therefore studied. Tumour cells showed a 4–100-fold increase in CD55 cell surface expression when
compared to normal cells. Immunohistochemical staining of colorectal tumours also revealed high expression of CD55 in the stroma. To
examine the source of this stromal CD55 the ability of both epithelial cells and endothelial cells to produce extracellular CD55 was measured.
Tumour cell lines deposit CD55 into their extracellular matrix (ECM) in direct proportion to their cell surface expression. In contrast the ECM
from HUVEC cells contained large amounts of CD55 despite expressing low levels of CD55 on their cell surface. Furthermore expression of
CD55 on HUVEC cells was increased by exposure to VEGF. Although it remains unclear why CD55 is upregulated in the tumour environment
its high level of expression on tumour cells and associated endothelium may explain why it is a good target for both imaging and
immunotherapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: CD55 (DAF), tumour expression; endothelium; stroma; vascular endothelial growth factor (VEGF) 
80
Received 27 September 1999 
Revised 3 February 2000 
Accepted 15 March 2000 
Correspondence to: LG Durrant 
British Journal of Cancer (2001) 84(1), 80–86
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2000.1570, available online at http://www.idealibrary.com on  http://www.bjcancer.comCD55 in the tumour environment 81
British Journal of Cancer (2001) 84(1), 80–86 © 2001 Cancer Research Campaign
and tumour-conditioned medium or VEGF (10–300 µg ml–1:
Zeneca, Alderley Park, UK) respectively for 48 h prior to
harvesting the HUVECs. Tumour-conditioned media was derived
from the MDA 231 breast cancer cell line. These were grown to
confluence and the media replaced with serum free M199:Hams
F12 medium. Following 24 h incubation the resultant conditioned
media was filtered for use with the HUVEC. Fresh media was used
to culture the control HUVECs. Freshly resected tumours were
finely minced and dissociated in collagenase (0.05%; Boehringer
Mannheim) and DNase (0.1%; Boehringer Mannheim) for 1 h at
37˚C. 
Monoclonal antibodies 
Monoclonal antibodies 791T/36 (IgG2b anti-791Tgp72; Embleton
et al, 1981), BRIC 216 (IgG1 anti-SCR 3 of CD55; Tate et al,
1989), BRIC 220 (IgG1 anti-SCR 1 of CD55; Tate et al, 1989),
BRIC 110 (IgG1 anti-SCR 2 of CD55; Spring et al, 1987; Coyne
et al, 1992) have been reported previously. BRIC 229 and E4.3
(Sparrow and Mckenzie, 1983) recognize CD59 and CD46 respect-
ively. The BRIC antibodies were purchased from the Blood Group
Reference laboratory (Bristol, UK). Normal mouse IgG (Sigma,
Dorset, UK) and 708 monoclonal antibody (IgG2b) was used as
negative control antibodies. 
Indirect immunofluorescence 
Cell lines were incubated with monoclonal antibody for 1 h at 4˚C.
Cells were washed twice in fresh media containing 1% FCS and
then incubated with FITC conjugated rabbit anti-mouse (1/100,
Dako, High Wycombe, UK). Cells were analysed on a FACSscan
(Becton Dickinson, Sunnyvale CA, USA). Fluorescein fluores-
cence was excited at 488 nm and collected via a 10 nm band with
band pass filter centred at 515 nm after adjustment for standard
conditions using fluorochrome-labelled latex beads. Fluorescence
intensity expressed as mean linear fluorescence (MLF) was
calculated by multiplying the contents of each channel by its
channel number and dividing by the total number of cells in the
distribution. 
Immunohistochemistry 
Sections (5 µm) were cut from cryopreserved tumour blocks, air
dried overnight and rehydrated with Tris buffered saline (TBS).
Sections were preincubated with 100 µl of 20% rabbit serum for
20 min prior to the addition of 100 µl of the primary antibodies
(791T/36, 216, 220 or 110) to consecutive sections of tumour.
After 1 h the slides were washed and 100 µl of rabbit anti-mouse
conjugated to horseradish peroxidase (Sigma) was added in TBS
containing 4% human serum. Staining was developed with 3,3'-
diaminobenzidine-tetrahydrochloride (DAB-Sigma). After 10 min
the slides were transferred to a 0.5% copper sulphate bath for
10 min and then stained with haematoxylin. Slides were then
dehydrated and mounted. 
Western blotting 
Cells were washed twice with PBS and solubilized in 1% 
octyl-glucoside (Sigma) in lysis buffer (20 mM Tris.HCl pH 8.0,
150 mM NaCl). After half an hour at 4˚C, the samples were
centrifuged at 13 000 rpm for 10 minutes. The supernatant was
removed to a clean tube and centrifuged again at 100 000 g for
30 min. Cell lysates (from between 5 × 105 and 1 × 107 according
to cell type) were loaded on to SDS-PAGE under non-reducing
conditions. Proteins were transferred to nitrocellulose membrane
and blocked with PBS containing BSA (1%) for 1 h at room
temperature. After two washes with PBS-Tween (0.1%), primary
antibody was added for 1 h at room temperature. The blots were
washed twice and rabbit anti-mouse HRP-conjugate (Dako)
diluted 1:1000 was added. Following 1 h incubation and 3 washes,
the blots were developed by enhanced chemilluminescence (ECL)
system (Amersham-Pharmacia Biotech, Bucks, UK). 
Preparation and screening of extracellular matrix (ECM)
for CD55 
CD55 was measured in ECM as previously described (Hindmarsh
and Marks, 1998). HUVEC and tumour cells were cultured on 96-
well flat-bottom plates and maintained for up to 7 days post-
confluence by replacement of culture media every 1–3 days.
Post-confluent cells were removed using 0.02% EDTA in PBS at
37˚C, leaving the ECM attached to the plate. ECM was washed
3 times with PBS and used immediately. After blocking with 1%
BSA for 1 h, 791T/36 monoclonal antibody or the IgG2b control
antibody 708 was added to the plates for 1 h prior to washing twice
with PBS-Tween 20 (0.05%). The plates were incubated with
conjugated rabbit anti-mouse horseradish peroxidase (Dako)
diluted 1:1000 for a further 1 h. Plates were washed 3–4 times in
PBS with Tween 20 (0.05%) and developed with ABTS (Sigma).
Colour development was measured after 15–30 min at 405 nm. 
RESULTS 
Expression of CD55 was studied on a panel of tumour and normal
cells by indirect immunofluorescence and flow cytometric
analysis (Table 1). Cells were stained with the anti-tumour mono-
clonal antibody 791T/36, which binds to domains 1 and 2 of
CD55, and BRIC 220, 110 and 216 monoclonal antibodies, which
bind to CD55 SCR domains 1, 2 and 3 respectively. The normal
cells in this study have low level of expression of CD55. In
contrast, however, the tumour cell lines showed a 5–100-fold
increase in expression of CD55. The only exception was Colo205
that failed to show any increased expression of CD55. The
colorectal cell lines expressed 5–18 fold more than the normal
gastrointestinal cells. The gastric cell lines showed an even greater
increase in expression (35–53-fold) and the osteosarcoma cell line
(791T) showed the strongest expression (>100 fold). The level of
expression was also confirmed using the well-characterized anti-
CD55 antibodies BRIC 110, 216 and 220, which showed slight
variations from the levels obtained with 791T/36. By comparison
total cellular pools of CD55 were analysed by SDS-PAGE and
Western blotting using the monoclonal antibody BRIC 216 
(Fig. 1). 1–2 × 107 red blood cells or T-cells were required to
obtain a visible band, compared to 1 × 105 tumour cells that gave a
band of approximately 4-fold greater intensity. The overall level of
expression correlated well with the immunofluorescence results
with 791T > MKN45K > HT29 > C170 > HUVEC > lympho-
cytes = red blood cells, suggesting that most of the CD55 pool was
membrane associated. Slight variations in size were observed
among CD55 isolated from various cells. 791T, HT29, C170,
HUVEC and lymphocytes express a 72 kDa form, whereas the
band in MKN45 is slightly larger and the band in red blood cells82 L Li et al
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smaller. 791T cells and to a lesser extent C170 cells also express a
second 66 kDa isoform. 
To determine if the over-expression of CD55 observed on estab-
lished cell lines could also be seen in tumours in situ, 17 freshly
resected colorectal (Figure 2A) and 18 gastric tumours (Figure 2B)
were disaggregated and stained with the anti-CD55 monoclonal
antibody 791T/36 for analysis by FACS. For comparison normal
mucosa (Figure 2C), obtained from the operation resection
margins and 4 resected adenomas (Figure 2D) were also disag-
gregated and stained with 791T/36. Similar levels of CD55 expres-
sion were observed on the primary colorectal tumours as were seen
on the established cell lines. One colorectal tumour failed to
express CD55, whereas a further two showed similar levels to
normal gastrointestinal cells. 80% of the colorectal tumours
showed 4–50-fold increases in CD55 expression. The gastric
tumour cells showed very similar expression levels to the col-
orectal tumours. 83% had a 6–60-fold increase in CD55 expres-
sion, with one negative and two displaying normal levels of
expression. The adenomas had similar levels of CD55 to the
normal gastrointestinal mucosal samples. 
A possible reason for over-expression of a protein may be to
compensate for a deficiency of another functionally related
protein. In the complement control protein family there are two
other membrane associated regulators of complement, CD46
(Membrane Cofactor Protein, MCP) and CD59 (protectin).
Analysis of the tumour cells for expression of CD46 and CD59
showed elevated levels of both molecules compared to normal
cells (Table 1). 
Immunohistochemical staining of colorectal tumours shows
very strong stromal staining with the anti-CD55 monoclonal anti-
bodies (Fig. 3). To identify the source of this extracellular CD55
both tumour and endothelial cells were assessed for their ability to
secrete CD55. The supermatant from both cell types was used in
ELISA to measure the presence of soluble CD55. Neither the
tumour cell lines nor the endothelial cells were shown to secrete
significant amounts of CD55 (data not shown). In contrast all
tumour cells deposited CD55 into their ECM and the level
appeared proportional to their cell surface expression. In contrast
the extracellular matrix from HUVEC contained almost as much
CD55 as 791T extracellular matrix despite expressing 28 fold less
CD55 (HUVEC, MLF 90 and 791T, MLF 2589) on their cell
surface (Fig. 4). 
The growth characteristics of endothelial cells are known to be
affected by soluble growth factors in the tumour environment. To
test the effect of tumours on endothelial expression of CD55,
HUVECs were cultured in tumour-conditioned media (TCM).
Figure 5A shows 2–4 fold increases in CD55 cell surface expres-
sion when HUVEC were grown in TCM from the breast cell line
Table 1 Expression of CD55 on normal cells and tumour cell lines 
Cellsa Origin Staining (MLFb) with mouse monoclonal antibodies recognizing: Mouse IgGc T:N ratiod
CD55 CD46 CD59
791T/36 110 216 220 E4.3 229
Tumour cell lines 
791T Osteosarcoma 2631 2005 2376 2160 540 3982 40 104 
C170 Colorectal 412 246 302 271 650 1700 17 16 
HT29 Colorectal 495 312 388 339 778 852 30 18 
SW480 Colorectal 160 85 88 85 ND ND 25 5 
Colo205 Colorectal 63 34 28 27 912 356 34 1 
PTO1 Colorectal 167 190 161 166 ND ND 14 6 
MKN45K Gastric 995 731 1022 728 800 1900 121 35 
MKN45 Gastric 1387 1355 1317 1444 ND ND 70 53 
Normal cells 
Red blood cells 60 53 94 101 ND ND 27 1 
HUVECs 146 112 130 101 66 ND 56 4 
Lymphocytes 60 51 54 51 ND ND 4 2 
Monocytes 64 ND 67 ND 101 396 8 2 
Gastrointestinal epithelial cells 35 ND ND ND ND ND 10 1 
aCells were harvested, washed, stained by indirect immunofluorescence and analysed by flow cytometry. bResults are expressed as mean linear fluorescence. 
cPolyclonal mouse IgG was used as a negative control for all antibodies. MLF tumour cell line 791T/36-MLF normal mouse. dT:N ratio is defined as MLF GI
epithelial cells 791T/36-MLF normal mouse. ND-Not determined. 
Cell Number
X106
Lane
Normal cells Tumour cells
KDa
72
66
123456789 1 0
1 10 2 1 0.5 (a) 0.25 2 2 2
Figure 1 Western blot analysis of CD55 expression on cells. The cell
lysates were analysed by non-reducing SDS-PAGE and transferred to
nitrocellulose membrane. The blots were incubated with the anti-CD55
monoclonal antibody BRIC 216 diluted 1:500, then with rabbit anti-mouse
conjugated HRPO (1:1000) and developed using the ECL system. Lanes; 
1) HUVEC (1 × 106); 2) Erythrocytes (1 × 107); 3) T cells (2 × 106); 4) MG63
cells (1 × 106); 5) 791T cells (5 × 105); 6) (a) Approximately 150 ng of CD55
affinity purified from 791T cells; 7) 791T cells (0.25 × 105); 8) MKN45K cells
(2 × 106); 9) HT29 cells (2 × 106). 10) C170 cells (2 × 106) CD55 in the tumour environment 83
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MDA 231. This cell line is known to be angiogenic and secretes
high levels of VEGF (results not shown). The expression of CD55
in response to varying doses of VEGF was therefore studied
(Figure 5B). CD55 expression doubled with as little as 30 ng/ml of
VEGF. Higher doses only showed a slight further increase. 
DISCUSSION 
CD55 has recently been shown to be the target for the tumour
imaging monoclonal antibody 791T/36 and for the colorectal
cancer vaccine, 105AD7. Cloning and sequencing of CD55 from
tumour cells revealed that there were no mutations that would
account for it being a specific target antigen on tumour cells
(Spendlove et al, 1999). The relative levels of CD55 on tumour
and normal cells were therefore studied. 
All the normal cells in this study (endothelial cells, blood cells
and gastrointestinal epithelial cells) expressed low levels of CD55
as determined by both immunofluorescence and Western blotting
with a panel of anti-CD55 monoclonal antibodies. In contrast the
majority of tumours over-expressed this antigen. The degree of
over-expression varied widely with some tumours showing modest
over-expression (2–10 fold) and others showing very high levels
(>50 fold increase over normal cells). Similar results were obtained
with established cell lines or tumour cells released from freshly
resected tumours. Antibodies recognizing different domains of
CD55 showed slightly different levels of binding to cells derived
from different tissues. This may be related to the levels of glycosy-
lation of CD55 in different tissues, which may affect the accessi-
bility of each antibody. The high level of expression of CD55 by
tumours has been noted in a number of other studies using
immunohistochemical staining to monitor expression levels
(Niehans et al, 1996). Furthermore this elevated level of expression
is an independent indicator of prognosis with tumours that over-
express CD55 progressing more rapidly (Buckley et al, 1996). 
It has been proposed that over-expression of one of the comple-
ment inhibitory proteins (CIPs) may be a compensatory mecha-
nism for the loss of another. The most notable variation in
expression levels of the CIPs is in breast tumours assayed by
immunohistochemistry where they demonstrated variable loss of
one or more inhibitors (Niehans et al, 1996). In the gastric and
colorectal tumour cell lines in this study all 3 CIPs, CD55, CD46
and CD59, were elevated. 
In this study only two primary tumours failed to express CD55.
Loss of CD55 expression is an infrequent occurrence in tumours
with the notable exception of leukaemias. Here the loss of expression
has been attributed to the loss of ability to synthesize a GPI-anchor
and abnormal transcriptional regulation (Hatanaka et al, 1996). The
absence of CD55 may leave cells vulnerable to complement-
mediated lysis. However, the elevated levels of CD46 and CD59
observed on these cells should compensate for the absence of CD55. 
Interestingly, immunohistochemistry of colorectal tumours with
anti-CD55 monoclonal antibodies shows intense staining of the
extracellular matrix. Both tumour and endothelial cells contribute
to the extended stromal matrix within tumours. Previous studies
have shown that both endothelial cells and the HeLa cell line can
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Figure 2 Freshly isolated (A) colorectal tumour, (B) gastric tumour, (C)
normal epithelium and (D) adenomas were disaggregated by collagenase
treatment, stained by indirect immunofluorescence with 791T/36 monoclonal
antibody and analysed by flow cytometry. Results are expressed as the mean
linear fluorescence per tumour case 
A
Figure 3 Immunohistochemical staining of a colon tumour. Tumour sections
were stained with (A) 216 monoclonal antibody and (B) normal mouse IgG.
S defines tumour stroma and A adjacent mucosa 
B84 L Li et al
British Journal of Cancer (2001) 84(1), 80–86 © 2001 Cancer Research Campaign
release CD55 into their ECM (Hindmarsh and Marks, 1998). This
study has extended this observation to include osteosarcoma and
colorectal cell lines. Furthermore it has shown that the amount of
CD55 deposited into the ECM by tumour cells was proportional to
cell surface expression. However, in endothelial cells, although the
cell surface expression was similar to normal epithelia, the level of
CD55 deposited into the ECM was closer to the levels deposited
by the highest expressing tumour cell lines. Furthermore CD55
expression on endothelial cells was upregulated in the presence of
both VEGF and tumour-conditioned media. Similar increases in
expression of CD55 have also been reported with TNF-α , IL-1β ,
IL-4 and hypoxia (Collard et al, 1997; Hindmarsh and Marks
1998). Our data suggests that the tumour environment causes
upregulation of CD55 on tumour-associated endothelium. Indeed
Niehans et al (1996) observed high endothelial expression of
CD55 in human cancers. The mechanism of CD55 deposition into
the ECM is unclear. Previous studies have shown that HT29 cells
can directly secrete CD55 without incorporating it into their cell
membrane (Nasu et al, 1998). In contrast other studies have shown
that tumour cells can flip phospholipase from the internal to the
external membrane surface where it can specifically cleave GPI-
anchored proteins. However, both of these mechanisms would also
result in release of CD55 into culture supernatant. In this study
only very low levels of CD55 could be detected in supernatant
suggesting an alternative mechanism of CD55 deposition into
ECM was taking place. Perhaps CD55 is covalently linked to
cellular matrix proteins before it is exported from the cell?
Whatever the mechanism of CD55 deposition into ECM it appears
to remain functionally active as Hela derived ECM can efficiently
deactivate complement (Hindmarsh and Marks, 1998). 
It remains unclear as to why the tumour environment is such a
rich source of CD55 when normal cells are protected from comple-
ment with more modest levels. This may be related to other
emerging functions of CD55. It has recently been shown that
CD55, like CD59, can act as a costimulator in submitogenically
activated T-cells, resulting in secretion of IL-2 and cell prolifer-
ation (Tosello et al, 1998). Alternatively CD55 has recently been
shown to be the ligand for CD97, an early activation marker
expressed by activated leukocytes (Hamann et al, 1996). This
raises the possibility that there may be epithelial leukocyte cross
talk. 
Numerous studies in patients with osteosarcoma, breast, ovarian
and colorectal cancer have shown that radiolabelled 791T/36
monoclonal antibody localizes well in 70% of primary and
metastatic lesions (Armitage et al, 1985). This study shows that
791T/36 could be localizing within the tumour either by binding to
CD55 on tumour cells or within the stroma. Indeed autoradiog-
raphy of resected tumours from patients imaged with radiolabelled
791T/36 showed intense stromal localization of the antibody
(Armitage et al, 1984). Similarly over-expression of CD55 by
Figure 4 Expression and deposition in the extracellular matrix of CD55 by
tumour and endothelial cells. Tumour and endothelial cells were grown to
confluence, removed from the culture wells by treatment with EDTA and both
the cells and the extracellular matrix (ECM) were assayed for CD55. (A) Cells
were measured by indirect immunofluorescence with 791T/36 and analysed
by flow cytometry. Results are expressed as mean linear fluorescence.
Normal mouse IgG was used as a negative control. (B) The extracellular
matrix was assessed by 791T/36 ELISA. Monoclonal antibody 708 was used
as a negative control 
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tumours makes it a good potential target for T cells. Other studies
have shown that over-expressed self-antigens can be effective
targets for cancer vaccines. When cytotoxic T lymphocytes
(CTLs) specific to wild type p53 peptides were transferred to 
p53-bearing nude mice they caused complete and permanent
tumour eradication. Importantly, this occurred in the absence of
any demonstrable damage to normal tissue suggesting wild 
type p53-specific CTLs could discriminate between p53 over-
expressing tumour cells and normal tissue (Vierboom et al, 1997).
Similarly immunization with telomerase caused stimulation of
CTLs that killed leukaemia cells expressing high levels of telom-
erase but failed to kill haematopoietic stem cells that expressed
more modest levels of this enzyme (Vonderheide et al, 1999). This
selective killing is thought to be related to the ability of T cells to
count peptides associated with MHC (Lanzavecchia et al, 1999).
The level of MHC occupancy of a normally expressed antigen is
insufficient to allow effector T-cell triggering. However, increased
antigen expression on tumours can raise the level of MHC occu-
pancy to the threshold for T cell triggering. The relative levels of
antigen expression between tumour and normal cells will
depend upon peptide/MHC/TCR affinities. Levels of expression of
CD55 on tumours compared to that on normal tissue make this
molecule a good target for immunotherapy. This is evident in trials
in colorectal cancer patients with the anti-idiotypic antibody that
mimics CD55 (Denton et al, 1994; Durrant et al, 1999; Maxwell-
Armstrong et al, 1999). These patients demonstrate T-cell
responses to antigen-positive tumours, infiltration of activated
CD4 and CD56 lymphocytes and a significant increase in tumour
cell apoptosis compared to unimmunized patients. Administration
of this vaccine to over 170 patients with colorectal cancer has
resulted in no discernible normal tissue toxicity, suggesting that
the level of expression on tumour cells marks these cells as targets,
leaving normal cells unaffected. 
Colorectal and gastric tumours over-express CD55 that can be
targeted by antibody and cell-mediated immunotherapy. The en-
vironment of the tumour also results in upregulation of endothelial
cell surface-associated CD55 and an increase in the ability of these
cells to secrete CD55 into their extracellular matrix. This may
make CD55 a target on both tumour cells and the endothelium
associated with the tumour. 
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